Extract Value from Natural and Chemically Modified Compounds

Pre-clinical porfolio of microbiome-derived immune-modulating peptides with exclusive technologies and the sicnetific expertise for discovering, expanding and advancing a valuable IO/I pipeline.

Primary Strategy:

• • Deep dive into metabolome
  • • Concentratio if minor metabolites
  • • Fractionanation to simplified pools for testing
  • • High rate of structured novelty
  • • Priority driven by biological activity (IP created)
  • • Potential to go directly to the organism
  
  

  Derivative strategy:

  • • Modify major metabolites
  • • Novel chemistry creates IP positions
  • • Abundant by-product compounds
  • • One-step chemistry transforms ADME properties
  • • Available for broad screening as pure compounds
  • • Synthetic GMP (IP creates)